Más Información

Estrenan documental sobre Helio Flores en la Cineteca Nacional; el caricaturista pide que se mantenga la caricatura política y no se use IA

Sheinbaum no presentará demanda contra Elon Musk por dichos que la vinculan con cárteles; "si sigue, lo reevaluaremos", advierte

Aureliano Hernández Palacios, economista y maestro en Políticas Públicas; es el nuevo titular de la Auditoría Superior

“Quienes nacieron in vitro no forman parte de la familia”; ministra María Estela Ríos desata polémica en sesión de la Corte

Se mantiene la Fase 1 de la Contingencia Ambiental en el Valle de México; continúan restricciones vehiculares
Mexico’s Foreign Affairs Minister Marcelo Ebrard Casaubón announced that Mexico has reached agreements with three companies that are developing COVID-19 vaccines to perform late-stage clinical trials in our country.
During president Andrés Manuel López Obrador’s morning news conference, Minister Ebrard said they are two companies from China and one from the United States, with which – he said – our country is participating in four protocols for the development of the vaccine.
The company from the United States is Janssen Pharmaceutical while the ones from China are Cansino Biologics and Walvax Technology.
As part of the memorandum of understanding, the late stage of the clinical protocols for the vaccine will take place in Mexico, that is, there will be clinical trials in our country from September 2020 through January 2021.
Recommended:
Moreover, Ebrard Casaubón said Mexico is working with 15 companies so that our country has timely access to the vaccine against the new disease once it is developed.
The Foreign Affairs Minister said our country was the first one to make a proposal in that regard at the G20 meeting and to present a related initiative that was unanimously approved at the United Nations.

In the case of Mexican citizens that have been repatriated due to the coronavirus pandemic, Marcelo Ebrard said that so far, the government has helped 16,874 Mexicans abroad.
Recommended:
mp
Noticias según tus intereses
[Publicidad]
[Publicidad]









